Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease (Q28820783)

Forecasting the global burden of Alzheimer’s disease

Europe PubMed Central

title

Memoquin: a multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer's disease (English)

0 references

1 reference

Maria Laura Bolognesi

series ordinal

1

0 references

Andrea Cavalli

series ordinal

2

0 references

Carlo Melchiorre

series ordinal

3

0 references

language of work or name

English

0 references

publication date

January 2009

0 references

published in

Neurotherapeutics

0 references

volume

6

0 references

issue

1

0 references

page(s)

152-62

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Global prevalence of dementia: a Delphi consensus study

16 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Drug discovery: playing dirty

16 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

16 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Crystal structure of mouse acetylcholinesterase. A peripheral site-occluding loop in a tetrameric assembly

16 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

From dual binding site acetylcholinesterase inhibitors to multi-target-directed ligands (MTDLs): a step forward in the treatment of Alzheimer's disease

16 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Treatment options in Alzheimer's disease: maximizing benefit, managing expectations

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Bis-(-)-nor-meptazinols as novel nanomolar cholinesterase inhibitors with high inhibitory potency on amyloid-beta aggregation

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Multi-target-directed ligands to combat neurodegenerative diseases

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

A review of compliance to treatment in Alzheimer's disease: potential benefits of a transdermal patch

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Oxidative stress: A dead end or a laboratory hypothesis?

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

How to understand the dichotomy of antioxidants

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Alzheimer's disease: a lesson from mitochondrial dysfunction.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

100 years and counting: prospects for defeating Alzheimer's disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Disease modifying therapy for AD?

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Dimeric and hybrid anti-Alzheimer drug candidates

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Discovery of acetylcholinesterase peripheral anionic site ligands through computational refinement of a directed library

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Pharmacologic principles for combination therapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Acetylcholinesterase inhibitors for the treatment of dementia in Alzheimer's disease: do we need new inhibitors?

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Designed multiple ligands. An emerging drug discovery paradigm

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

In vivo optical imaging of amyloid aggregates in brain: design of fluorescent markers

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Utilizing combination therapy in the treatment of Alzheimer's disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Oxidative stress mechanisms and potential therapeutics in Alzheimer disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Acetylcholinesterase inhibitors as a starting point towards improved Alzheimer's disease therapeutics

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Induction of quinone reductase as a primary screen for natural product anticarcinogens

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Regional NAD(P)H:quinone oxidoreductase activity in Alzheimer's disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Secretases as targets for the treatment of Alzheimer's disease: the prospects

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Polymethylene tetraamine backbone as template for the development of biologically active polyamines

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Beta-amyloid plaques in a model for sporadic Alzheimer's disease based on transgenic anti-nerve growth factor antibodies

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Alzheimer's disease and Abeta toxicity: from top to bottom

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Anti-amyloidogenic activity of tetracyclines: studies in vitro.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

NAD(P)H:quinone oxidoreductase activity is increased in hippocampal pyramidal neurons of patients with Aalzheimer's disease.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Alzheimer-like neurodegeneration in aged antinerve growth factor transgenic mice

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Antioxidant properties of 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone (idebenone).

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Acetylcholinesterase promotes the aggregation of amyloid-beta-peptide fragments by forming a complex with the growing fibrils.

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Therapeutic potential of CNS-active M2 antagonists: novel structures and pharmacology

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5084263

Alzheimer disease is multifactorial and heterogeneous.

3 June 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.10.042

Brain acetylcholinesterase promotes amyloid-beta-peptide aggregation but does not hydrolyze amyloid precursor protein peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.10.042

Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.10.042

Idebenone protects hippocampal neurons against amyloid beta-peptide-induced neurotoxicity in rat primary cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.10.042

A small molecule targeting the multifactorial nature of Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.10.042

beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.10.042

Propidium-based polyamine ligands as potent inhibitors of acetylcholinesterase and acetylcholinesterase-induced amyloid-beta aggregation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.10.042

3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.10.042

Novel donepezil-based inhibitors of acetyl- and butyrylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.10.042

Preformed beta-amyloid fibrils are destabilized by coenzyme Q10 in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.10.042

Inhibition of amyloid beta protein aggregation and neurotoxicity by rifampicin. Its possible function as a hydroxyl radical scavenger.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.10.042

Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.10.042

Therapies for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.NURT.2008.10.042

Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19110206

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Quinone reductase (NQO1), a sensitive redox indicator, is increased in Alzheimer's disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19110206